ImmuCell (NASDAQ:ICCC – Get Rating) will post its quarterly earnings results after the market closes on Thursday, August 11th. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
ImmuCell (NASDAQ:ICCC – Get Rating) last announced its quarterly earnings data on Thursday, May 12th. The biotechnology company reported $0.09 EPS for the quarter. ImmuCell had a net margin of 5.20% and a return on equity of 3.36%. The business had revenue of $6.00 million during the quarter.
ImmuCell Stock Performance
Shares of NASDAQ ICCC opened at $9.03 on Thursday. The company has a current ratio of 7.78, a quick ratio of 6.32 and a debt-to-equity ratio of 0.30. ImmuCell has a 12 month low of $7.30 and a 12 month high of $10.96. The company has a 50 day simple moving average of $8.43 and a two-hundred day simple moving average of $8.63. The stock has a market cap of $69.92 million, a price-to-earnings ratio of 64.50 and a beta of 0.58.
Institutional Investors Weigh In On ImmuCell
Analyst Ratings Changes
Separately, Aegis reiterated a “buy” rating on shares of ImmuCell in a research note on Thursday, June 23rd.
ImmuCell Company Profile
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.
- Get a free copy of the StockNews.com research report on ImmuCell (ICCC)
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- There Are Different Types of Stock To Invest In
- Is Starbucks Shooting For The Moon?
- Two High-Yield Deep-Values You Shouldn’t Ignore
- PayPal Continues To Struggle As Competition Increases
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.